Tag: HS-20089

GSK and Duality Biologics have entered into an exclusive option agreement for developing and commercializing DB-1324, a potentially best-in-class antibody-drug conjugate (ADC) candidate.

Over the past five years China has emerged as a major force in the research and development of innovative therapies for the treatment of...